| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| J A Smith, C Boyer-Millar, A J Goudi. Does MK-801 discrimination constitute an animal model of schizophrenia useful for detecting atypical antipsychotics? Pharmacology, biochemistry, and behavior. vol 64. issue 2. 1999-12-20. PMID:10515325. |
does mk-801 discrimination constitute an animal model of schizophrenia useful for detecting atypical antipsychotics? |
1999-12-20 |
2023-08-12 |
rat |
| S Ami. Cost-effectiveness of atypical antipsychotics in chronic schizophrenia. Hospital medicine (London, England : 1998). vol 60. issue 6. 1999-10-14. PMID:10492711. |
cost-effectiveness of atypical antipsychotics in chronic schizophrenia. |
1999-10-14 |
2023-08-12 |
Not clear |
| L J Cohe. The role of neuropsychiatric pharmacists. The Journal of clinical psychiatry. vol 60 Suppl 19. 1999-10-05. PMID:10507281. |
more than 80% of patients with schizophrenia who are treated with conventional neuroleptics are rehospitalized within 2 years, and controlled studies have shown that inpatient costs are lower when atypical antipsychotics are used instead of typical antipsychotics. |
1999-10-05 |
2023-08-12 |
Not clear |
| F Tascedda, E Lovati, J M Blom, P Muzzioli, N Brunello, G Racagni, M A Riv. Regulation of ionotropic glutamate receptors in the rat brain in response to the atypical antipsychotic seroquel (quetiapine fumarate). Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 21. issue 2. 1999-09-14. PMID:10432469. |
the differences between classical and atypical antipsychotics, as well as among the novel agents, might be relevant for specific aspects of their therapeutic activity and could provide valuable information for the role of glutamate in specific symptoms of schizophrenia. |
1999-09-14 |
2023-08-12 |
rat |
| Y C Chan, S F Pariser, G Neufel. Atypical antipsychotics in older adults. Pharmacotherapy. vol 19. issue 7. 1999-09-03. PMID:10417029. |
the superior safety and efficacy of atypical antipsychotics makes them first-line agents for managing psychotic patients with schizophrenia. |
1999-09-03 |
2023-08-12 |
human |
| T I Prior, P S Chue, P Tibbo, G B Bake. Drug metabolism and atypical antipsychotics. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 9. issue 4. 1999-09-03. PMID:10422890. |
the introduction of the atypical antipsychotics clozapine, risperidone, olanzapine, quetiapine and sertindole for the treatment of schizophrenia has coincided with an increased awareness of the potential of drug-drug interactions, particularly involving the cytochrome p450 (cyp) enzymes. |
1999-09-03 |
2023-08-12 |
Not clear |
| D A Revick. Pharmacoeconomic studies of atypical antipsychotic drugs for the treatment of schizophrenia. Schizophrenia research. vol 35 Suppl. 1999-07-21. PMID:10190231. |
the pharmacoeconomic evaluation of atypical antipsychotics for patients with schizophrenia requires focus on both clinical and quality of life effects and impact on the cost of medical resources. |
1999-07-21 |
2023-08-12 |
Not clear |
| M Campbell, P I Young, D N Bateman, J M Smith, S H Thoma. The use of atypical antipsychotics in the management of schizophrenia. British journal of clinical pharmacology. vol 47. issue 1. 1999-06-18. PMID:10073734. |
the use of atypical antipsychotics in the management of schizophrenia. |
1999-06-18 |
2023-08-12 |
Not clear |
| C L DeVan. No mourning for the conventional antipsychotics: the dawn of the atypical agents. The Annals of pharmacotherapy. vol 33. issue 1. 1999-03-29. PMID:9972392. |
explain, the atypical antipsychotics should become the first-line agents for the treatment of schizophrenia. |
1999-03-29 |
2023-08-12 |
Not clear |
| G Chouinard, L Kopala, A Labelle, L Beauclair, S V Johnson, K I Sing. Phase-IV multicentre clinical study of risperidone in the treatment of outpatients with schizophrenia. The RIS-CAN-3 Study Group. Canadian journal of psychiatry. Revue canadienne de psychiatrie. vol 43. issue 10. 1999-03-18. PMID:9868567. |
since most clinical trials of atypical antipsychotics have been conducted in hospitalized patients, a phase-iv, multicentre, 8-week, open-label, flexible-dose study was performed to assess the efficacy and safety of risperidone in outpatients with schizophrenia. |
1999-03-18 |
2023-08-12 |
Not clear |
| H Y Meltze. Outcome in schizophrenia: beyond symptom reduction. The Journal of clinical psychiatry. vol 60 Suppl 3. 1999-03-15. PMID:10073370. |
evidence exists that the atypical antipsychotics not only reduce positive and negative symptoms and cause fewer side effects than conventional neuroleptics, but also lessen cognitive impairment, lead to a better quality of life, and have antidepressant effects, all of which should result in improved outcome in patients with schizophrenia. |
1999-03-15 |
2023-08-12 |
Not clear |
| R Lewi. Typical and atypical antipsychotics in adolescent schizophrenia: efficacy, tolerability, and differential sensitivity to extrapyramidal symptoms. Canadian journal of psychiatry. Revue canadienne de psychiatrie. vol 43. issue 6. 1999-01-26. PMID:9729687. |
typical and atypical antipsychotics in adolescent schizophrenia: efficacy, tolerability, and differential sensitivity to extrapyramidal symptoms. |
1999-01-26 |
2023-08-12 |
Not clear |
| D V Jeste, J B Lohr, J H Eastham, E Rockwell, M P Caligiur. Adverse neurobiological effects of long-term use of neuroleptics: human and animal studies. Journal of psychiatric research. vol 32. issue 3-4. 1998-12-30. PMID:9793874. |
atypical antipsychotics may produce improvement in cognitive performance in patients with chronic schizophrenia. |
1998-12-30 |
2023-08-12 |
human |
| Measuring outcome in schizophrenia: differences among the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations. The Journal of clinical psychiatry. vol 59 Suppl 12. 1998-10-20. PMID:9766613. |
measuring outcome in schizophrenia: differences among the atypical antipsychotics. |
1998-10-20 |
2023-08-12 |
Not clear |
| Assessing the effects of atypical antipsychotics on negative symptoms. Collaborative Working Group on Clinical Trial Evaluations. The Journal of clinical psychiatry. vol 59 Suppl 12. 1998-10-20. PMID:9766617. |
attempts to clarify the domains of schizophrenia gained importance when the atypical antipsychotics joined the armamentarium of schizophrenia treatments because of evidence that these agents are superior to conventional antipsychotics for the treatment of negative symptoms. |
1998-10-20 |
2023-08-12 |
Not clear |
| Atypical antipsychotics for treatment of depression in schizophrenia and affective disorders. Collaborative Working Group on Clinical Trial Evaluations. The Journal of clinical psychiatry. vol 59 Suppl 12. 1998-10-20. PMID:9766619. |
atypical antipsychotics for treatment of depression in schizophrenia and affective disorders. |
1998-10-20 |
2023-08-12 |
Not clear |
| Treatment of special populations with the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations. The Journal of clinical psychiatry. vol 59 Suppl 12. 1998-10-20. PMID:9766620. |
atypical antipsychotics have become the treatment of choice for patients experiencing a first episode of schizophrenia. |
1998-10-20 |
2023-08-12 |
Not clear |
| D A Collie. Atypical antipsychotics, schizophrenia and cortical 5-HT2A receptors. Molecular psychiatry. vol 3. issue 3. 1998-10-08. PMID:9672893. |
atypical antipsychotics, schizophrenia and cortical 5-ht2a receptors. |
1998-10-08 |
2023-08-12 |
Not clear |
| C Andersson, M Chakos, R Mailman, J Lieberma. Emerging roles for novel antipsychotic medications in the treatment of schizophrenia. The Psychiatric clinics of North America. vol 21. issue 1. 1998-07-10. PMID:9551495. |
the recent advent of atypical antipsychotics has provided new clinical options and set higher expectations for the treatment of schizophrenia. |
1998-07-10 |
2023-08-12 |
Not clear |
| T Sharma, D Mockle. The cognitive efficacy of atypical antipsychotics in schizophrenia. Journal of clinical psychopharmacology. vol 18. issue 2 Suppl 1. 1998-06-12. PMID:9555611. |
the cognitive efficacy of atypical antipsychotics in schizophrenia. |
1998-06-12 |
2023-08-12 |
Not clear |